Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX HELSINKI LTD.  >  DNA Oyj    DNA   FI4000062385

DNA OYJ

(DNA)
  Report
SummaryNewsRatingsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

DNA Plc: Telenor Finland Holding Oy has gained title to all outstanding shares in DNA and the DNA shares have been delisted from Nasdaq Helsinki

02/03/2020 | 10:05am EST

DNA PLC STOCK EXCHANGE RELEASE 3 February 2020, 5:05 pm EET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR SUCH OTHER COUNTRIES OR OTHERWISE IN SUCH CIRCUMSTANCES IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Telenor Finland Holding Oy ("Telenor") has on 3 February 2020 posted a security approved by the arbitral tribunal for the payment of the redemption price and the interest accruing thereon and thereby obtained title to all minority shares in DNA Oyj ("DNA") in accordance with Chapter 18, Section 6 of the Finnish Companies Act ("Companies Act"). After the security has been posted and the title to the shares transferred, the minority shareholders of DNA being parties to the redemption proceedings are entitled to receive only the redemption price and the interest payable thereon.

Upon DNA's application, Nasdaq Helsinki Ltd ("Nasdaq Helsinki") has on 17 December 2019 decided that DNA's shares will be delisted from the official list of Nasdaq Helsinki after Telenor has obtained title to all the outstanding shares in DNA in the redemption proceedings in accordance with the Companies Act. The trading in DNA's shares on Nasdaq Helsinki has been suspended on 30 January 2020 and the DNA shares have today been delisted in accordance with separate releases published by Nasdaq Helsinki.

After the delisting of the shares in DNA, DNA is not subject to reporting obligations as an issuer of shares as set out in the Finnish Securities Markets Act. The delisting of the shares in DNA does not affect DNA's reporting obligations in its capacity of the issuer of senior unsecured fixed rate notes due 2025 (ISIN: FI4000312095).

DNA Plc

Further enquiries:
Marja Mäkinen, Head of IR, DNA Plc, +358 44 044 1262, marja.makinen@dna.fi
DNA Corporate Communications, +358 44 044 8000, communications@dna.fi

DNA is one of the leading telecommunications companies in Finland. We want to make our customers' daily lives less complicated. We offer connections, services and devices for homes and workplaces, contributing to the digitalisation of society. DNA’s mobile communication network customers have the highest mobile data usage per subscription in the world. We are Finland's largest cable TV operator. DNA has more than 4 million subscriptions in its fixed and mobile communications networks. The company was ranked the best employer in Finland in the large companies’ category of the 2019 Great Place to Work survey. In 2019, our net sales were EUR 942.1 million and we employ about 1,600 people around Finland. DNA is a part of Telenor Group, the leading ICT company in the Nordics. Additional information: www.dna.fi, Twitter @DNA_fi, Facebook @DNA.fi and LinkedIn.

 

© OMX, source OMX

All news about DNA OYJ
2020Investor Stroll eyes sharing Formula One tech with Aston Martin road cars
RE
2020Sanofi teams up with U.S. agency against coronavirus
RE
2020Can a 'numbers guy' with insurance DNA finally fix AIG?
RE
2020WHAT THE EU WANTS : Commission outlines post-Brexit deal with London
RE
2020DNA PLC : Telenor Finland Holding Oy has gained title to all outstanding shares ..
AQ
2020DNA PLC : Arbitral tribunal has confirmed Telenor Finland Holding Oy's redemptio..
AQ
2020DNA OYJ : Plc's Financial Statements Bulletin 2019
AQ
2020Illumina abandons $1.2 billion deal to buy rival Pacific Biosciences
RE
2019AstraZeneca, Merck score win with Lynparza approval for pancreatic cancer
RE
2019DNA OYJ : financial information and Annual General Meeting in 2020
AQ
More news
Financials
Sales 2019 942 M 1 147 M 1 147 M
Net income 2019 98,8 M 120 M 120 M
Net Debt 2019 559 M 680 M 680 M
P/E ratio 2019 27,9x
Yield 2019 -
Capitalization 2 755 M 3 030 M 3 353 M
EV / Sales 2018 2,89x
EV / Sales 2019 3,52x
Nbr of Employees 1 639
Free-Float 98,9%
Income Statement Evolution
Managers and Directors
NameTitle
Jukka Tapani Leinonen Chief Executive Officer
Jørgen Christian Rostrup Chairman
Timo Juhani Karppinen Chief Financial Officer
Tommy Christian Olenius Senior Vice President-Technology
Janne Aalto Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
DNA OYJ-0.10%3 038
VERIZON COMMUNICATIONS INC.-2.89%236 947
CHARTER COMMUNICATIONS, INC.-2.83%128 484
NIPPON TELEGRAPH AND TELEPHONE CORPORATION3.19%96 126
DEUTSCHE TELEKOM AG1.24%86 872
SAUDI TELECOM COMPANY5.09%59 443